Sciclone Pharmaceuticals Inc
SCLN
SCLN was delisted on the 13th of October, 2017.
129 hedge funds and large institutions have $394M invested in Sciclone Pharmaceuticals Inc in 2017 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 47 increasing their positions, 41 reducing their positions, and 25 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
182% more call options, than puts
Call options by funds: $214K | Put options by funds: $76K
15% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 41
6% less capital invested
Capital invested by funds: $422M → $394M (-$27.3M)
9% less funds holding
Funds holding: 142 → 129 (-13)
44% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GP
GLG Partners
London,
United Kingdom
|
+$11M |
| 2 |
MWNA
Marshall Wace North America
New York
|
+$6.63M |
| 3 |
FPF
FNY Partners Fund
New York
|
+$3.62M |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$3.54M |
| 5 |
Ohio Public Employees Retirement System (OPERS)
Columbus,
Ohio
|
+$2.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$27.9M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$19.3M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
-$4.48M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.8M |
| 5 |
Fisher Asset Management
Camas,
Washington
|
-$2.49M |
SCLN Hedge Fund Activity: Q3 2017 in Review
129 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals Inc (SCLN) for Q3 2017, worth a combined $394M — down 6.5% from $422M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of SCLN and 14 opened new positions — a net loss of 11 holders — while 41 trimmed existing stakes and 47 added.
The largest buyer was GLG Partners, adding an estimated $11M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $27.9M sold.
- 129 institutional investors held Sciclone Pharmaceuticals Inc (SCLN) as of Q3 2017, down from 142 in Q2 2017.
- Funds reported $394M of Sciclone Pharmaceuticals Inc stock for Q3 2017, down 6.5% quarter-over-quarter.
- 14 funds opened new Sciclone Pharmaceuticals Inc positions in Q3 2017 and 25 closed out, a net change of -11 holders.
- The largest Sciclone Pharmaceuticals Inc buyer in Q3 2017 was GLG Partners, an estimated $11M added.
- The largest Sciclone Pharmaceuticals Inc seller in Q3 2017 was Renaissance Technologies, an estimated $27.9M sold.
Based on aggregated 13F filings for Q3 2017.